121 related articles for article (PubMed ID: 37001446)
1. DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
Arend R; Dholakia J; Castro C; Matulonis U; Hamilton E; Jackson CG; LyBarger K; Goodman HM; Duska LR; Mahdi H; ElNaggar AC; Kagey MH; Liu A; Piper D; Barroilhet LM; Bradley W; Sachdev J; Sirard CA; O'Malley DM; Birrer M
Gynecol Oncol; 2023 May; 172():82-91. PubMed ID: 37001446
[TBL] [Abstract][Full Text] [Related]
2. Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer.
Goyal L; Sirard C; Schrag M; Kagey MH; Eads JR; Stein S; El-Khoueiry AB; Manji GA; Abrams TA; Khorana AA; Miksad R; Mahalingam D; Zhu AX; Duda DG
Clin Cancer Res; 2020 Dec; 26(23):6158-6167. PubMed ID: 32878766
[TBL] [Abstract][Full Text] [Related]
3. Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers.
Klempner SJ; Bendell JC; Villaflor VM; Tenner LL; Stein SM; Rottman JB; Naik GS; Sirard CA; Kagey MH; Chaney MF; Strickler JH
Mol Cancer Ther; 2021 Nov; 20(11):2240-2249. PubMed ID: 34482288
[TBL] [Abstract][Full Text] [Related]
4. The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer.
Wall JA; Klempner SJ; Arend RC
Expert Opin Investig Drugs; 2020 Jul; 29(7):639-644. PubMed ID: 32408777
[TBL] [Abstract][Full Text] [Related]
5. A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Wise DR; Pachynski RK; Denmeade SR; Aggarwal RR; Deng J; Febles VA; Balar AV; Economides MP; Loomis C; Selvaraj S; Haas M; Kagey MH; Newman W; Baum J; Troxel AB; Griglun S; Leis D; Yang N; Aranchiy V; Machado S; Waalkes E; Gargano G; Soamchand N; Puranik A; Chattopadhyay P; Fedal E; Deng FM; Ren Q; Chiriboga L; Melamed J; Sirard CA; Wong KK
Prostate Cancer Prostatic Dis; 2024 Feb; ():. PubMed ID: 38341461
[TBL] [Abstract][Full Text] [Related]
6. Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.
Fuh KC; Bookman MA; Liu JF; Coleman RL; Herzog TJ; Thaker PH; Monk BJ; Anderson R; McIntyre G; Rangwala R; Moore KN
Gynecol Oncol; 2021 Nov; 163(2):254-261. PubMed ID: 34474927
[TBL] [Abstract][Full Text] [Related]
7. Validation of a DKK1 RNAscope chromogenic in situ hybridization assay for gastric and gastroesophageal junction adenocarcinoma tumors.
Caldwell C; Rottman JB; Paces W; Bueche E; Reitsma S; Gibb J; Adisetiyo V; Haas MS; Heath H; Newman W; Baum J; Gianani R; Kagey MH
Sci Rep; 2021 May; 11(1):9920. PubMed ID: 33972574
[TBL] [Abstract][Full Text] [Related]
8. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
9. Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.
Backes FJ; Wei L; Chen M; Hill K; Dzwigalski K; Poi M; Phelps M; Salani R; Copeland LJ; Fowler JM; Cohn DE; Bixel K; Cosgrove C; Hays J; O'Malley D
Gynecol Oncol; 2021 Sep; 162(3):619-625. PubMed ID: 34272090
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Richardson DL; Sill MW; Coleman RL; Sood AK; Pearl ML; Kehoe SM; Carney ME; Hanjani P; Van Le L; Zhou XC; Alvarez Secord A; Gray HJ; Landrum LM; Lankes HA; Hu W; Aghajanian C
JAMA Oncol; 2018 Feb; 4(2):196-202. PubMed ID: 29242937
[TBL] [Abstract][Full Text] [Related]
11. Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.
Liu JF; Ray-Coquard I; Selle F; Poveda AM; Cibula D; Hirte H; Hilpert F; Raspagliesi F; Gladieff L; Harter P; Siena S; Del Campo JM; Tabah-Fisch I; Pearlberg J; Moyo V; Riahi K; Nering R; Kubasek W; Adiwijaya B; Czibere A; Naumann RW; Coleman RL; Vergote I; MacBeath G; Pujade-Lauraine E
J Clin Oncol; 2016 Dec; 34(36):4345-4353. PubMed ID: 27998236
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
Oza A; Kaye S; Van Tornout J; Sessa C; Gore M; Naumann RW; Hirte H; Colombo N; Chen J; Gorla S; Poondru S; Singh M; Steinberg J; Yuen G; Banerjee S
Gynecol Oncol; 2018 May; 149(2):275-282. PubMed ID: 29454514
[TBL] [Abstract][Full Text] [Related]
13. Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
Coleman RL; Handley KF; Burger R; Molin GZD; Stagg R; Sood AK; Moore KN
Gynecol Oncol; 2020 May; 157(2):386-391. PubMed ID: 32037195
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial.
Moreno V; Barretina-Ginesta MP; García-Donas J; Jayson GC; Roxburgh P; Vázquez RM; Michael A; Antón-Torres A; Brown R; Krige D; Champion B; McNeish I
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34893524
[TBL] [Abstract][Full Text] [Related]
15. Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer.
Betella I; Turbitt WJ; Szul T; Wu B; Martinez A; Katre A; Wall JA; Norian L; Birrer MJ; Arend R
Gynecol Oncol; 2020 Jun; 157(3):765-774. PubMed ID: 32192732
[TBL] [Abstract][Full Text] [Related]
16. mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Immune Responses in the Tumor Microenvironment.
Haas MS; Kagey MH; Heath H; Schuerpf F; Rottman JB; Newman W
Mol Cancer Res; 2021 Apr; 19(4):717-725. PubMed ID: 33443105
[TBL] [Abstract][Full Text] [Related]
17. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.
O'Malley DM; Richardson DL; Rheaume PS; Salani R; Eisenhauer EL; McCann GA; Fowler JM; Copeland LJ; Cohn DE; Backes FJ
Gynecol Oncol; 2011 May; 121(2):269-72. PubMed ID: 21315428
[TBL] [Abstract][Full Text] [Related]
18. Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
Aghajanian C; Swisher EM; Okamoto A; Steffensen KD; Bookman MA; Fleming GF; Friedlander M; Moore KN; Tewari KS; O'Malley DM; Chan JK; Ratajczak C; Hashiba H; Wu M; Dinh MH; Coleman RL
Gynecol Oncol; 2022 Feb; 164(2):278-287. PubMed ID: 34930617
[TBL] [Abstract][Full Text] [Related]
19. Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).
Emons G; Kurzeder C; Schmalfeldt B; Neuser P; de Gregorio N; Pfisterer J; Park-Simon TW; Mahner S; Schröder W; Lück HJ; Heubner ML; Hanker L; Thiel F; Hilpert F
Gynecol Oncol; 2016 Mar; 140(3):450-6. PubMed ID: 26731724
[TBL] [Abstract][Full Text] [Related]
20. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
